Cynata OTC Stock Financials

CYYNF -  USA Stock  

USD 0.40  0.00  0.00%

Understanding current and past Cynata Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Cynata Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Cynata Therapeutics' assets may result in an increase in income on the income statement. Because of this, it is necessary to analyze all of Cynata Therapeutics' financials over time to get the whole picture.
We suggest to use Cynata Therapeutics analysis to find out if markets are presently mispricing the company. We were able to interpolate twenty-three available fundamental indicators for Cynata Therapeutics, which can be compared to its rivals. To make sure the equity is not overpriced, please confirm all Cynata Therapeutics financials, including its gross profit, as well as the relationship between the current ratio and beta . As Cynata Therapeutics is a penny stock we also strongly suggest to validate its shares owned by insiders numbers. Use Cynata Therapeutics to protect your portfolios against small market fluctuations. The stock experiences a normal downward fluctuation but is a risky buy. Check odds of Cynata Therapeutics to be traded at $0.396 in 90 days.

Cynata Fundamentals 

With this module, you can analyze Cynata financials for your investing period. You should be able to track the changes in Cynata Therapeutics individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
Chance Of Financial Distress
Over 61
Cynata Therapeutics has more than 61 (%) percent chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for Cynata Therapeutics otc stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity. More Info
The data published in Cynata Therapeutics' official financial statements usually reflect Cynata Therapeutics' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Cynata Therapeutics. For example, before you start analyzing numbers published by Cynata accountants, it's critical to develop an understanding of what Cynata Therapeutics' liquidity, profitability, and earnings quality are in the context of the Cynata Therapeutics space in which it operates.
Please note, the presentation of Cynata Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Cynata Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Cynata Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Cynata Therapeutics. Please utilize our Beneish M Score to check the likelihood of Cynata Therapeutics' management to manipulate its earnings.

Cynata Therapeutics Company Summary

Cynata Therapeutics competes with Microsoft Corp, Bristol Myer, Alphabet, Apple, and AMERITRUST CORP. Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. Cynata Therapeutics Limited was founded in 2011 and is based in Cremorne, Australia. Cynata Therapeutics is traded on OTC Exchange in the United States.
InstrumentUSA OTC Stock View All
ExchangeOTC Exchange
Business Address100 Cubitt Street
Phone61 3 7067 6940
CurrencyUSD - US Dollar
You should never invest in Cynata Therapeutics without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Cynata OTC Stock, because this is throwing your money away. Analyzing the key information contained in Cynata Therapeutics' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

Cynata Therapeutics Key Financial Ratios

Generally speaking, Cynata Therapeutics' financial ratios allow both analysts and investors to convert raw data from Cynata Therapeutics' financial statements into concise, actionable information that can be used to evaluate the performance of Cynata Therapeutics over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Cynata Therapeutics reports annually and quarterly.

Cynata Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Cynata Therapeutics's current stock value. Our valuation model uses many indicators to compare Cynata Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Cynata Therapeutics competition to find correlations between indicators driving Cynata Therapeutics's intrinsic value. More Info.
Cynata Therapeutics is rated below average in revenue category among related companies. It is number one stock in price to sales category among related companies . The ratio of Revenue to Price to Sales for Cynata Therapeutics is about  63,499 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Cynata Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Cynata Therapeutics' OTC Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Cynata Therapeutics' earnings, one of the primary drivers of an investment's value.

Cynata Therapeutics Systematic Risk

Cynata Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Cynata Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Cynata Therapeutics correlated with the market. If Beta is less than 0 Cynata Therapeutics generally moves in the opposite direction as compared to the market. If Cynata Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Cynata Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Cynata Therapeutics is generally in the same direction as the market. If Beta > 1 Cynata Therapeutics moves generally in the same direction as, but more than the movement of the benchmark. View also all equity analysis or get more info about beta statistic functions indicator.

About Cynata Therapeutics Financials

What exactly are Cynata Therapeutics Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Cynata Therapeutics' income statement, its balance sheet, and the statement of cash flows. Potential Cynata Therapeutics investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Cynata Therapeutics investors may use each financial statement separately, they are all related. The changes in Cynata Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Cynata Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines that you should keep in mind when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase year after year due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt to equity ratio because this number will tell you how much risk it has. If a company such as Cynata Therapeutics is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to try and figure out if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that net revenue of Cynata grown by more than 25% over the last five years, then there is a good chance that it will continue growing at least by 20% or more each year. On the other hand, if you see that net revenue has only grown by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it.

Cynata Therapeutics November 28, 2021 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Cynata Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Cynata Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Cynata Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Cynata OTC Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Cynata Therapeutics's daily price indicators and compare them against related drivers.
Information Ratio0.1827
Maximum Drawdown12.12
Continue to Trending Equities. Note that the Cynata Therapeutics information on this page should be used as a complementary analysis to other Cynata Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for Cynata OTC Stock analysis

When running Cynata Therapeutics price analysis, check to measure Cynata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cynata Therapeutics is operating at the current time. Most of Cynata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cynata Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Cynata Therapeutics' price. Additionally, you may evaluate how the addition of Cynata Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Is Cynata Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cynata Therapeutics. If investors know Cynata will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cynata Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Cynata Therapeutics is measured differently than its book value, which is the value of Cynata that is recorded on the company's balance sheet. Investors also form their own opinion of Cynata Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cynata Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cynata Therapeutics' market value can be influenced by many factors that don't directly affect Cynata Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cynata Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Cynata Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cynata Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.